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The dioxins and dioxin-like compounds in cigarette smoke and environmental pollutants modulate immunological responses.
These environmental toxicants are known to cause lung cancer but have also recently been implicated in allergic and inﬂammatory
diseases such as bronchitis, asthma, and chronic obstructive pulmonary disease (COPD). In a novel pathway of this response,
the activation of a nuclear receptor, arylhydrocarbon receptor (AhR), mediates the eﬀects of these toxins through the arachidonic
acid cascade, cell diﬀerentiation, cell-cell adhesion interactions, cytokine expression, and mucin production that are implicated in
the pathogenesis and exacerbation of asthma/COPD. We have previously reported that human bronchial epithelial cells express
AhR, and AhR activation induces mucin production through reactive oxygen species. This review discusses the role of AhR in
asthma and COPD, focusing in particular on inﬂammatory and resident cells in the lung. We describe the important impact
that AhR activation may have on the inﬂammation phase in the pathology of asthma and COPD. In addition, crosstalk of AhR
signaling with other ligand-activated transcription factors such as peroxisome proliferator-activated receptors (PPARs) has been
well documented.
1.Introduction
Both allergic asthma and COPD are deﬁned as airway
inﬂammatory diseases; however, the inﬂammatory mech-
anism is diﬀerent for each disease. Nocuous agents such
as PCBs, B[a]P, and dioxin-like compounds in cigarette
smoke and environmental pollutants have the potential
to induce inﬂammation or exacerbate chronic bronchitis,
asthma, COPD, and lung cancer [1–4]. In addition to airway
epithelial cells, many inﬂammatory cells, including Th2 cells,
eosinophils, and basophils, play a major pathophysiological
role in asthma and COPD [5–8]. Cigarette smoke and
environmental pollutants activate these inﬂammatory cells,
and they contribute to the activation of growth factors and
cytokines. For example, exposure to some types of noxious
agents increases the rate of TGF-α,T G F - β,I L - 1 β,I L - 6 ,I L -
8, and IFN-γ gene expression [9–12]. While the molecular
signaling mechanism for this transcriptional modulation of
cytokines remains to be determined, it has been recently
recognized that these eﬀects are mainly mediated through
the binding of noxious agents to the AhR. All major human
cell types express AhR, including pulmonary tissue [13, 14].
The liver, adipose tissue, and skin are the major storage sites
of AhR ligands in humans [15]. These AhR ligands are also
concentrated in bronchial epithelial cells, suggesting that the
respiratory system is sensitive to AhR ligands [16].
The AhR is a ligand-activated transcription factor, and
after ligation of dioxins to the AhR, the receptor translocates
from the cytosol to the nucleus, where it heterodimerizes
withtheARNT.ItthenbindstoaDRE,anenhancersequence
of several drug-metabolizing enzymes, such as CYP1A1 [17].
AhR-induced CYP1A1 activation is important for detoxica-
tion. CYPs convert B[a]P and dioxin-like compounds into
physiologic metabolites that exert eﬀects on cell growth,
diﬀerentiation, and migration. A number of researchers have
demonstrated the molecular aspects of the AhR pathway by
usingselectiveagonistssuchasTCDDorB[a]PamongPAHs.2 Journal of Allergy
In this review article, we summarize current ﬁndings
regarding the functional role of AhR molecules in airway
inﬂammation and focus on bronchial epithelial cells, ﬁbrob-
lasts, granulocytes, and lymphocytes. Understanding the
eﬀects of AhR on these cells would be a breakthrough in our
understandingofthepathologyandtreatmentofasthmaand
COPD.
2. AirwayInﬂammatory Effectthrough
Ah RA c ti vatio ninA sth m aandC O PD
2.1. Airway Epithelial Cells. Airway epithelial cells are able to
modify allergic airway inﬂammation by virtue of their ability
toproduceavarietyofinﬂammatorymediators[18,19].One
such mediator is the moderate bronchial mucin-containing
mucus, which normally protects the airway from exogenous
substances. Hypermucosis in the airway, however, is asso-
ciated with several respiratory diseases, including asthma
and COPD. Mucus hypersecretion in the airway increases
coughing and expectoration of sputum. Clara cells in the
airway can secrete a wide variety of glycoproteins, such as
mucins and SP-D, and are very sensitive to AhR stimulation
[20, 21]. Wong et al. recently have reported TCDD, an AhR
agonist, increased expression of inﬂammatory cytokines,
MUC5AC, and MMPs via AhR signaling in a Clara-cell-
derivedcellline[21].Mucusproductionistypicallymediated
by cytokine or lipid mediator release, or an increase of ROS
[22–24]. Studies using AhR agonists and inhibitors have
demonstrated that AhR activation induces the production
of cytokines such as TGF-α,T N F - α, and MMP through
receptors in human hematocytes and epithelial cells [21, 25–
27]. Wong et al. also reported an increase of COX-2 and IL-
1β mRNAexpressioninresponsetoAhRactivation[21].The
production of prostanoids such as PGE2, which is derived
from COX-2, can activate mucin production in the airway
[22]. Although prostaglandins derived from COX-2 pathway
activation may be responsible for AhR-induced mucin
production in the bronchial epithelial cells, the mechanism
of their action remains to be determined. Therefore, it is of
paramount interest to investigate the mechanism by which
AhR activation induces mucin production. In an earlier
study, we reported ﬁndings similar to those by Wong et
al. In our study, we found that AhR activation upregulates
the expression of MUC5AC and mucin secretion in a NCI-
H292 cell line that was derived from a bronchiolar Clara
cell [14]( Figure 1). Moreover, we concurrently showed that
AhR activation induced ROS generation, and the antioxidant
agent NAC inhibited B[a]P-induced MUC5AC upregulation.
Kopf and Walker also demonstrated that TCDD-induced
AhR activation increased ROS levels in endothelial cells [29].
Another prostaglandin, PGD2, is synthesized from arachi-
donic acid via the catalytic activities of COX in epithelial
cells and mast cells. It is released into the airway following
an antigen challenge during an acute allergic response [30].
PGD2 induces chemotaxis of Th2 cells, eosinophils, and
basophils as a consequence of the activation of its receptors
[31]. This suggests that PGD2 promotes inﬂammation in
allergic asthma. Prostaglandins that are derived from COX-
2 pathway activation and ROS that are induced by AhR
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Figure 1: Eﬀects of AhR agonist B[a]P on MUC5AC mRNA level in
NCI-H292 after 12h of incubation. MUC5AC was measured by real-
time RT-PCR. B[a]P induced MUC5AC mRNA expression in dose-
dependent manner. Pretreatment with AhR antagonist, resveratrol,
inhibited AhR-induced MUC5AC upregulation. Data are expressed
as means ± SD (n = 6).
∗P < 0.05 versus control (medium alone).
∗∗P < 0.05 versus B[a]P 1μM.
activation are the major inﬂammatory mediators capable of
inducing mucin production, inﬂammatory cell chemotaxis,
or inﬂammatory cell activation. Therefore, increased levels
of prostaglandins and ROS, either directly or through the
formation of lipid peroxidation products, may enhance the
inﬂammatory response in both asthma and COPD.
Neutrophils isolated from peripheral blood and BAL
ﬂuid of asthmatic patients generate more ROS than cells
from normal patients. Additionally, the production of ROS
correlates with the degree of airway hyperresponsiveness
[32, 33]. Neutrophils and macrophages are also known to
migrate into the lungs of COPD patients [34, 35]. Indeed,
the neutrophils that mediate ROS-induced injury to the
airway epithelium are responsible for hyperresponsiveness in
human peripheral airways, suggesting that neutrophils play
an important role in the pathogenesis of asthma and COPD
[36]. AhR-derived inﬂammatory mediators in airway epithe-
lial cells, such as IL-8 and leukotriene B4, may have a chemo-
tactic eﬀect. We previously conﬁrmed that normal human
epidermalkeratinocytes(NHEKs)enhancedIL-8production
through AhR activation [37]( Figure 2). Martinez et al.
demonstrated that IL-8 gene expression was upregulated by
TCDD in A549 cells from a bronchial epithelial cell line
[38]. However, they could not detect IL-8 production at
the protein level in airway epithelial cells. We were also
unable to detect IL-8 production from AhR-activation in
NCI-H292 cells using ELISA analysis (data not shown).
Although it is not clear that AhR directly modulates NF-κB,
the induction of a transcription factor for IL-8, tumor
necrosisfactor,orIL-1βbyAhRactivationmightimpactIL-8
production in airway epithelial cells [21, 25, 26, 39].
Cell-cell contact molecules in the airways create a barrier
that plays an important role in the defense against bacteria.Journal of Allergy 3
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Figure 2: Normal human epidermal keratinocytes (NHEKs) were
exposed to B[a]P at various concentrations for 24h, and IL-8
productionintheculturesupernatantwasmeasured.B[a]Pinduced
IL-8 production in a dose-dependent manner. Data are expressed as
means ± SD (n = 3).
∗P < 0.05 versus control (medium alone).
Loss of expression of cell-cell contact molecules, such as E-
cadherin, reduces the ability of epithelial cells to function
as a barrier and may increase the allergic response and
susceptibility to infection. Indeed, E-cadherin and α-catenin
interacted with cytosolic domain of the cadherin expression
are signiﬁcantly lower in asthmatic than in nonasthmatic
subjects [40]. AhR also regulates the expression of adhe-
sion molecules and consequently controls cell-cell contact.
Exposure to TCDD from a human breast cancer cell line
downregulates E-cadherin expression [41]. Using rat liver
epithelial cells, Dietrich et al. demonstrated that TCDD
exposure inhibits the expression of γ-catenin, which links E-
cadherin to actin ﬁlaments [42]. We hypothesize that several
pathwaysmaybeinvolvedintheproductionofinﬂammatory
cytokines and mucus in asthma and COPD, as illustrated in
Figure 3.
2.2. Fibroblast or Airway Smooth Muscle. Chronic asthmatic
patients who are unresponsive to treatment experience
progressive and irreversible changes in pulmonary function.
Thesechanges,knownas“airwayremodeling,”areassociated
with structural alterations, such as subepithelial ﬁbrosis,
smooth muscle or goblet cell hyperplasia, and airway hyper-
responsiveness [43]. In chronic asthma patients, ﬁbrosis is
due to increased deposition of extracellular matrix. Increases
in airway smooth muscle mass are thought to be caused by
faster proliferation, mitogenic, or inﬂammatory stimuli [44].
Some of the factors contributing to these eﬀects are TGF,
FGF, EGF, and PDGF. TGF-β is one of these contributors and
is a major eﬀector cytokine that can increase deposition by
ﬁbroblastsandairwaysmoothmusclehypertrophy.Guoetal.
reported that levels of RNA for TGF-β2a n dT G F - β2-related
genes increased in AhR-knockout smooth muscle cells [45].
This suggests that AhR may repress the TGF-β- signaling
pathway, resulting in an anti-inﬂammatory eﬀect unlike
in rodent lung cells. On the other hand, cigarette smoke,
via AhR, can induce cyclooxygenase and PGE2 in human
lung ﬁbroblasts [46]. PGE2 signiﬁcantly enhances cigarette
smoke extract-treated neutrophil chemotaxis and adhesion
to airway epithelial cells [47]. In fact, the concentration
of PGE2 in the sputum of COPD patients is correlated
with the number of inﬁltrating neutrophils [47]. Neutrophil
activation through AhR signaling plays a causal role in
pathogenesis and exacerbation of COPD.
2.3. Granulocytes with Focus on Eosinophils. Eosinophils play
an essential role in the pathology of asthma because they
contribute to tissue injury, vascular leakage, mucus secre-
tion, and tissue remodeling by releasing cytotoxic granule
proteins, ROS, and lipid mediators [48]. Because eosinophils
are the ﬁnal eﬀector cells in allergic inﬂammation, it is
important to study the process by which nuclear receptors,
such as AhR, activate eosinophils in order to understand
the pathogenesis of allergic diseases. For example, PPARs
are among the important ligand-activated transcription
factors that regulate the expression of genes involved in
many cellular functions, including diﬀerentiation, immune
responses, and inﬂammation [49, 50]. The PPAR subfamily
consists of 3 isotypes: PPARα,P P A R β/δ,a n dP P A R γ,a l lo f
which have been identiﬁed in eosinophils. These nuclear
receptors form heterodimers with retinoid X receptors, bind
to a speciﬁc DNA sequence (PPRE), and activate target gene
transcription. In vivo and in vitro evidence suggests that
PPARα and PPARγ expression in granulocytes and dendritic
cells plays a critical role as an inﬂammatory suppressive
regulator in allergic diseases. Treatment with the PPARγ
agonist, rosiglitazone, decreases the clinical severity of skin
lesions in atopic dermatitis and airway inﬂammation in
asthmatic patients [51, 52]. We previously demonstrated
that the PPARγ agonist troglitazone reduced IL-5-stimulated
eosinophil survival, eotaxin-directed eosinophil chemotaxis,
and functional augmentation of eosinophil adhesion in a
concentration-dependent manner. These changes occurred
without reducing the quantitative expression of β2 integrins
[53, 54]( Figure 4). It has been lately shown that PPARγ
induction is suppressed during the activation of the AhR
by TCDD [55]. In addition, Cho et al. demonstrated
that CYP1B1 upregulation induced the inhibition of AhR
expression in 10T1/2 cells derived from preadipocyte lines.
Moreover, the reduced AhR expression was accompanied by
an increase in PPARγ expression [56]. These results suggest
that the AhR signal may repress migration, degranulation,
and cellular adhesion of eosinophils. This may impair the
antiallergic eﬀects induced by PPARγ.W ew e r ea b l et oc o n -
ﬁrm AhR expression in human eosinophils using RT-PCR
(data not shown). Clariﬁcation of the interaction between
AhR and PPARγ signals should broaden our understanding
not only of the functional role of eosinophils but also of
asthma regulation.
2.4. Lymphocytes. Allergic asthma is associated with dis-
ruption of the immune system, particularly an imbalance
of Th1 and Th2 cells. It is well known that Th2 cells
play a key role in the regulation of inﬂammatory reactions
through the release of Th2 cytokines. AhR is known to exert
an inﬂuence on allergic immunoregulation. In fact, Tauchi
et al. reported that mice with constitutive AhR activation4 Journal of Allergy
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Figure 3: Schematic diagram of the proposed crosstalk AhR-signaling pathway and inﬂammatory eﬀects in airway epithelial cells.
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Figure 4:(a)EﬀectofPPARγ agonisttroglitazoneoneosinophilchemotaxisstimulatedwitheotaxin.Puriﬁedeosinophilswerepreincubated
with increasing concentrations of troglitazone for 1h. Migration assays were performed using Boyden chambers. Chemotactic response to
eotaxin alone was considered to be 100%, and reactions to lower concentrations are presented relative to eotaxin alone. Data are expressed
as mean ± SD. Troglitazone inhibited the eotaxin-directed eosinophil chemotaxis in a dose-dependent manner (n = 4).
∗P < 0.05
versus eotaxin alone. (b) Eﬀect of troglitazone on eosinophil survival determined by staining with Annexin V-FITC and propidium iodine.
Eosinophils were incubated with and without troglitazone in the presence of 1ng/mL IL-5 for 48h. Eosinophils were treated with Annexin
V to stain early-phase apoptotic cells and with propidium iodine (PI) to stain the late-phase cells. The bar graph shows a dose-dependent
eﬀect of troglitazone on IL-5-induced eosinophil survival (n = 4). Data are expressed as mean ± SD.
∗P < 0.05 versus without troglitazone.Journal of Allergy 5
developed severe skin lesions that were similar to the lesions
seen in atopic dermatitis. The lesions were accompanied by
high serum levels of IgE and increased production of IL-
4 and IL-5 from stimulated splenic lymphocytes [57]. In
addition, AhR expression in splenic B cells was enhanced
by the presence of lipopolysaccharide, which is known to
exacerbateasthmaandCOPD[58].PAHandTCDDincrease
IgEproductionincocultureswithpuriﬁedBcells[59].These
resultsprovidefurtherevidencethatAhRmayplayacomplex
roleinthehumoralimmunologicalbalanceinairwayallergic
pathogenesis.
Th17 cells have been recently classiﬁed as a subtype
of helper T cells that are characterized by the production
of IL-17 [60]. AhR activation promotes the development
of Th17 cells and results in increased pathology in animal
models of multiple sclerosis [61]. Th17 cells found in the
skin, gastrointestinal tract, and bronchial tubes are involved
in inﬂammatory conditions, such as inﬂammatory bowel
disease and asthma [62]. The IL-17 produced by Th17 cells
is a potent activator of NF-κB, thereby, increasing the levels
of inﬂammatory cytokines such as IL-8, IL-6, TNF-α,G -
CSF, and GM-CSF [63]. Therefore, although Th17 plays
a role in regulating neutrophil and macrophage inﬂam-
mation, it is not known whether IL-17 induced by AhR
activation contributes to the development of asthma or
COPD. Clinically, IL-17 levels in BAL ﬂuid, sputum, and
peripheral blood from patients with allergic asthma are
higher than those in healthy controls [64, 65]. A knockout
mouse model of the IL-17 receptor showed reduced OVA-
induced airway hyperresponsiveness and eosinophil inﬁltra-
tion. Additionally, the levels of IgE and Th2 cytokines in
knockout mice were not as highly elevated as they were in
wild-type mice [66]. Furthermore, stimulation with IL-17
increased the concentration of biologically active MMP-9 in
mouse airways. IL-17 protein, as represented by neutrophilic
inﬂammation, has been detected in COPD patients, but at
a lower level than observed in asthma patients [67]. Human
lymphocytes, however, may behave diﬀerently. For example,
AhR agonists appear to favor IL-22 but not IL-17 production
in humans [68]. These studies suggest a role of AhR-induced
Th17 in promoting allergic or inﬂammatory airway diseases,
but there are interesting diﬀerences between human and
mouse T cells. These diﬀerences suggest that the response to
AhR activation may vary according to cell type, maturation,
and diﬀerentiation process.
3. Conclusion
We reviewed studies on the relationship between AhR
function and airway inﬂammation, as it is important in the
initial phase of asthma/COPD. In addition to studying the
toxicological eﬀects, we wish to promote studies focused
on the immune regulation of endogenous AhR pathways.
Moreover, it seems increasingly apparent that AhR acts
by competing with other nuclear receptors in a complex
manner. Further investigation may yield a novel treatment
strategy for AhR-associated lung diseases.
Abbreviations
PCBs: Polychlorinated biphenyls
B[a]P: Benzopyrene
COPD: Chronic obstructive pulmonary disease
TGF-α: Transforming growth factor alpha
AhR: Arylhydrocarbon receptor
ARNT: AhR nuclear translocator
DRE: Dioxin response element
CYP1A1: Cytochrome P450 1A1
TCDD: 2,3,7,8-tetrachlorodibenzo-p-dioxin
ROS: Reactive oxygen species
TNF-α: Tumor necrosis factor alpha
MMP: Matrix metalloproteases
COX-2: Cyclooxygenase-2
PGE2: Prostaglandin E2
PGD2: Prostaglandin D2
MUC5AC: Oligomeric mucus/gel forming
BAL: Bronchoalveolar lavage
PPARs: Peroxisome proliferator-activated receptors
PPRE: PPARs response element
IgE: Immunoglobulin E
G-CSF: Granulocyte colony-stimulating factor
FGF: Fibroblast growth factor
EGF: Epidermal growth factor
PDGF: Platelet-derived growth factor.
Acknowledgments
This work was supported by the Environment Technology
Development Fund of the Ministry of the Environment of
Japan and in part by the Ministry of Health, Labour, and
Welfare of Japan.
References
[1] T. K. Baginski, K. Dabbagh, C. Satjawatcharaphong, and D.
C.Swinney, “Cigarette smoke synergistically enhances respira-
tory mucin induction by proinﬂammatory stimuli,” American
Journal of Respiratory Cell and Molecular Biology, vol. 35, no.
2, pp. 165–174, 2006.
[2] N. B. Marshall and N. I. Kerkvliet, “Dioxin and immune re-
gulation: emerging role of aryl hydrocarbon receptor in the
generation of regulatory T cells,” Annals of the New York
Academy of Sciences, vol. 1183, pp. 25–37, 2010.
[ 3 ]D .R .P a t e la n dD .N .H o m n i c k ,“ P u l m o n a r ye ﬀects of smok-
ing,” Adolescent Medicine, vol. 11, no. 3, pp. 567–576, 2000.
[4] American Thoracic Society, “Standards for the diagnosis and
care of patients with chronic obstructive pulmonary disease
(COPD) and asthma,” American Review of Respiratory Dis-
eases, vol. 136, pp. 225–243, 1987.
[5] H. Lai and D. F. Rogers, “New pharmacotherapy for airway
mucus hypersecretion in asthma and COPD: targeting intra-
cellular signaling pathways,” Journal of Aerosol Medicine and
Pulmonary Drug Delivery, vol. 23, no. 4, pp. 219–231, 2010.
[6] P. J. Barnes, “Immunology of asthma and chronic obstructive
pulmonary disease,” Nature Reviews Immunology, vol. 8, no. 3,
pp. 183–192, 2008.
[7] T. Mauad and M. Dolhnikoﬀ, “Pathologic similarities and dif-
ferences between asthma and chronic obstructive pulmonary
disease,” Current Opinion in Pulmonary Medicine, vol. 14, no.
1, pp. 31–38, 2008.6 Journal of Allergy
[ 8 ]M .N .H y l k e m a ,P .J .S t e r k ,W .I .d eB o e r ,a n dD .S .P o s t m a ,
“Tobacco use in relation to COPD and asthma,” European
Respiratory Journal, vol. 29, no. 3, pp. 438–445, 2007.
[ 9 ]Z .W .L a i ,C .H u n d e i k e r ,E .G l e i c h m a n n ,a n dC .E s s e r ,“ C y -
tokine gene expression during ontogeny in murine thymus
on activation of the aryl hydrocarbon receptor by 2,3,7,8-
tetrachlorodibenzo-p-dioxin,” Molecular Pharmacology, vol.
52, no. 1, pp. 30–37, 1997.
[ 1 0 ]C .V o g e la n dJ .A b e l ,“ E ﬀect of 2,3,7,8-tetrachlorodibenzo-p-
dioxinongrowthfactorexpressioninthehumanbreastcancer
cell line MCF-7,” Archives of Toxicology, vol. 69, no. 4, pp. 259–
265, 1995.
[11] C. Vogel, S. Donat, O. D¨ ohr et al., “Eﬀect of subchronic 2,3,
7,8-tetrachlorodibenzo-p-dioxin exposure on immune system
and target gene responses in mice: calculation of benchmark
doses for CYP1A1 and CYPIA2 related enzyme activities,”
Archives of Toxicology, vol. 71, no. 6, pp. 372–382, 1997.
[12] T. K. Warren, K. A. Mitchell, and B. P. Lawrence, “Exposure to
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) suppresses the
humoral and cell-mediated immune responses to inﬂuenza A
virus without aﬀecting cytolytic activity in the lung,” Toxico-
logical Sciences, vol. 56, no. 1, pp. 114–123, 2000.
[13] M. Ema, N. Matsushita, K. Sogawa et al., “Human arylhy-
drocarbon receptor: functional expression and chromosomal
assignment to 7p21,” Journal of Biochemistry, vol. 116, no. 4,
pp. 845–851, 1994.
[14] T. Chiba, H. Uchi, G. Tsuji, H. Gondo, Y. Moroi, and M.
Furue, “Arylhydrocarbon receptor (AhR) activation in airway
epithelial cells induces MUC5AC via reactive oxygen species
(ROS) production,” Pulmonary Pharmacology and Therapeu-
tics, vol. 24, pp. 133–140, 2011.
[ 1 5 ] M .V a nd e nB e r g ,J .D eJ o n g h ,H .P o i g e r ,a n dJ .R .O l s o n ,“T h e
toxicokinetics and metabolism of polychlorinated dibenzo-p-
dioxins (PCDDs) and dibenzofurans (PCDFs) and their rele-
vance for toxicity,” Critical Reviews in Toxicology, vol. 24, no.
1, pp. 1–74, 1994.
[16] K. Alexandrov, M. Rojas, and S. Satarug, “The critical DNA
damage by benzo(a)pyrene in lung tissues of smokers and
approaches to preventing its formation,” Toxicology Letters,
vol. 198, no. 1, pp. 63–68, 2010.
[17] J. Mimura and Y. Fujii-Kuriyama, “Functional role of AhR
in the expression of toxic eﬀects by TCDD,” Biochimica et
Biophysica Acta, vol. 1619, no. 3, pp. 263–268, 2003.
[18] J.H.Wang, C.J.Trigg, J.L.Devalia, S.Jordan,andR.J.Davies,
“Eﬀect ofinhaled beclomethasonedipropionateonexpression
of proinﬂammatory cytokines and activated eosinophils in the
bronchial epithelium of patients with mild asthma,” Journal
of Allergy and Clinical Immunology, vol. 94, no. 6 I, pp. 1025–
1034, 1994.
[19] S. Ying, Q. Meng, K. Zeibecoglou et al., “Eosinophil chemo-
tactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte
chemoattractant protein-3 (MCP-3), and MCP-4), and C-
C chemokine receptor 3 expression in bronchial biopsies
from atopic and nonatopic (intrinsic) asthmatics,” Journal of
Immunology, vol. 163, no. 11, pp. 6321–6329, 1999.
[20] A. M. Tritscher, J. Mahler, C. J. Portier, G. W. Lucier, and N.
J. Walker, “Induction of lung lesions in female rats follow-
ing chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin,”
Toxicologic Pathology, vol. 28, no. 6, pp. 761–769, 2000.
[21] P. S. Wong, C. F. Vogel, K. Kokosinski, and F. Matsumura,
“Arylhydrocarbon receptor activation in NCI-H441 cells and
C57BL/6 mice: possible mechanisms for lung dysfunction,”
AmericanJournalofRespiratoryCellandMolecularBiology,vol.
42, no. 2, pp. 210–217, 2010.
[22] K. E. White, Q. Ding, B. B. Moore et al., “Prostaglandin E2
mediates IL-1β-related ﬁbroblast mitogenic eﬀects in acute
lung injury through diﬀerential utilization of prostanoid
receptors,”JournalofImmunology,vol.180,no.1,pp.637–646,
2008.
[23] J. M. Lora, D. M. Zhang, S. M. Liao et al., “Tumor necrosis
factor-alpha triggers mucus production in airway epithelium
through an IkappaB kinase beta-dependent mechanism,”
Journal of Biological Chemistry, vol. 280, no. 43, pp. 36510–
36517, 2005.
[24] M. Perrais, P. Pigny, M. C. Copin, J. P. Aubert, and I. Van
Seuningen, “Induction of MUC2 and MUC5AC mucins by
factors of the epidermal growth factor (EGF) family is medi-
ated by EGF receptor/Ras/Raf/extracellular signal-regulated
kinase cascade and Sp1,” Journal of Biological Chemistry, vol.
277, no. 35, pp. 32258–32267, 2002.
[25] H. Cheon, Y. S. Woo, J. Y. Lee et al., “Signaling pathway
for 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced TNF-α pro-
duction in diﬀerentiated THP-1 human macrophages,” Exper-
imental and Molecular Medicine, vol. 39, no. 4, pp. 524–534,
2007.
[26] J. W. Davis Jr., A. D. Burdick, F. T. Lauer, and S. W. Burchiel,
“The aryl hydrocarbon receptor antagonist, 3  methoxy-4  ni-
troﬂavone, attenuates 2,3,7,8-tetrachlorodibenzo-p-dioxin-
dependent regulationof growthfactor signalingand apoptosis
in the MCF-10A cell line,” Toxicology and Applied Pharmacol-
ogy, vol. 188, no. 1, pp. 42–49, 2003.
[27] M. Ishida, S. Mikami, E. Kikuchi et al., “Activation of the aryl
hydrocarbon receptor pathway enhances cancer cell invasion
by upregulating the MMP expression and is associated with
poor prognosis in upper urinary tract urothelial cancer,”
Carcinogenesis, vol. 31, no. 2, Article ID bgp222, pp. 287–295,
2010.
[28] K. E. White, Q. Ding, B. B. Moore et al., “Prostaglandin E2
mediates IL-1β-related ﬁbroblast mitogenic eﬀects in acute
lung injury through diﬀerential utilization of prostanoid
receptors,”JournalofImmunology,vol.180,no.1,pp.637–646,
2008.
[29] P. G. Kopf and M. K. Walker, “2,3,7,8-tetrachlorodibenzo-p-
dioxin increases reactive oxygen species production in human
endothelial cells via induction of cytochrome P4501A1,”
Toxicology and Applied Pharmacology, vol. 245, no. 1, pp. 91–
99, 2010.
[30] J. J. Murray, A. B. Tonnel, A. R. Brash et al., “Release of pros-
taglandin D 2 into human airways during acute antigen
challenge,” The New England Journal of Medicine, vol. 315, pp.
800–804, 1986.
[31] T. Chiba, A. Kanda, S. Ueki et al., “Possible novel receptor
for PGD2 on human bronchial epithelial cells,” International
Archives of Allergy and Immunology, vol. 143, supplement 1,
pp. 23–27, 2007.
[32] J. Seltzer, B. G. Bigby, M. Stulbarg et al., “O3-induced change
in bronchial reactivity to methacholine and airway inﬂamma-
tion in humans,” Journal of Applied Physiology, vol. 60, pp.
1321–1326, 1986.
[33] T. J. N. Hiltermann, E. A. Peters, B. Alberts et al., “Ozone-
induced airway hyperresponsiveness in patients with asthma:
role of neutrophil-derived serine proteinases,” Free Radical
Biology and Medicine, vol. 24, no. 6, pp. 952–958, 1998.
[34] M. Saetta, G. Turato, P. Maestrelli, C. E. Mapp, and L. M.
Fabbri, “Cellular and structural bases of chronic obstructive
pulmonary disease,” American Journal of Respiratory and
Critical Care Medicine, vol. 163, no. 6, pp. 1304–1309, 2001.Journal of Allergy 7
[35] P. J. Barnes, “Mediators of chronic obstructive pulmonary dis-
ease,” Cell and Molecular Biology, vol. 50, pp. OL627–OL637,
2004.
[36] P. Kirkham and I. Rahman, “Oxidative stress in asthma and
COPD: antioxidants as a therapeutic strategy,” Pharmacology
and Therapeutics, vol. 111, no. 2, pp. 476–479, 2006.
[37] G. Tsuji, M. Takahara, H. Uchi et al., “An environmental
contaminant, benzo(a)pyrene, induces oxidative stress-medi-
ated interleukin-8 production in human keratinocytes via
the aryl hydrocarbon receptor signaling pathway,” Journal of
Dermatological Science, vol. 62, pp. 42–49, 2011.
[38] J. M. Martinez, C. A. Afshari, P. R. Bushel, A. Masuda, T.
T a k a h a s h i ,a n dN .J .W a l k e r ,“ D i ﬀerential toxicogenomic re-
sponses to 2,3,7,8-tetrachlorodibenzo-p-dioxin in malignant
and nonmalignant human airway epithelial cells,” Toxicologi-
cal Sciences, vol. 69, no. 2, pp. 409–423, 2002.
[39] T. J. Standiford, S. L. Kunkel, M. A. Basha et al., “Interleukin-
8 gene expression by a pulmonary epithelial cell line. A
model for cytokine networks in the lung,” Journal of Clinical
Investigation, vol. 86, no. 6, pp. 1945–1953, 1990.
[40] W. I. de Boer, H. S. Sharma, S. M. Baelemans, H. C.
Hooqsteden, B. N. Lambrecht, and G. J. Braunstahl, “Altered
expression of epithelial junctional proteins in atopic asthma:
possible role in inﬂammation,” Canadian Journal of Physiology
and Pharmacology, vol. 86, pp. 105–112, 2008.
[41] L. L. Collins, B. J. Lew, and B. P. Lawrence, “TCDD exposure
disrupts mammary epithelial cell diﬀerentiation and func-
tion,” Reproductive Toxicology, vol. 28, no. 1, pp. 11–17, 2009.
[42] C. Dietrich, D. Faust, M. Moskwa, A. Kunz, K. W. Bock, and F.
Oesch,“TCDD-dependentdownregulationofgamma-catenin
in rat liver epithelial cells (WB-F344),” InternationalJournalof
Cancer, vol. 103, no. 4, pp. 435–439, 2003.
[ 4 3 ] W .B u s s e ,J .E l i a s ,D .S h e p p a r d ,a n dS .B a n k s - S c h l e g e l ,“ A i rw a y
remodeling and repair,” American Journal of Respiratory and
Critical Care Medicine, vol. 160, no. 3, pp. 1035–1042, 1999.
[44] Y. Sumi and Q. Hamid, “Airway remodeling in asthma,” Aller-
gology International, vol. 56, no. 4, pp. 341–348, 2007.
[45] J. Guo, M. Sartor, S. Karyala et al., “Expression of genes in
the TGF-beta signaling pathway is signiﬁcantly deregulated in
smooth muscle cells from aorta of aryl hydrocarbon receptor
knockout mice,” Toxicology and Applied Pharmacology, vol.
194, no. 1, pp. 79–89, 2004.
[46] C. A. Martey, C. J. Baglole, T. A. Gasiewicz, P. J. Sime, and
R. P. Phipps, “The aryl hydrocarbon receptor is a regulator of
cigarette smoke induction of the cyclooxygenase and pros-
taglandin pathways in human lung ﬁbroblasts,” American
Journal of Physiology, vol. 289, no. 3, pp. L391–L399, 2005.
[47] M. Proﬁta, A. Sala, A. Bonanno et al., “Chronic obstructive
pulmonarydiseaseandneutrophilinﬁltration:roleofcigarette
smoke and cyclooxygenase products,” American Journal of
Physiology, vol. 298, no. 2, pp. 261–269, 2010.
[48] H. Kita, C. R. Adolphason, and G. J. Gleich, “Biology of eos-
inophils,” in Middleton’s Allergy: Principles and Practice,N .F .
Anderson, J. W. Yunginger, W. W. Busse, B. S. Bochner, S.
T. Holgate, and F. E. Simons, Eds., pp. 305–332, Mosby,
Philadelphia, Pa, USA, 2003.
[ 4 9 ]I .I s s e m a n na n dS .G r e e n ,“ A c t i v a t i o no fam e m b e ro ft h e
steroid hormone receptor superfamily by peroxisome prolif-
erators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[50] S. A. Kliewer, J. M. Lehmann, and T. M. Willson, “Orphan
nuclear receptors: shifting endocrinology into reverse,” Sci-
ence, vol. 284, no. 5415, pp. 757–760, 1999.
[51] R. Behshad, K. D. Cooper, and N. J. Korman, “A retrospective
case series review of the peroxisome proliferator-activated
receptor ligand rosiglitazone in the treatment of atopic der-
matitis,” Archives of Dermatology, vol. 144, no. 1, pp. 84–88,
2008.
[52] M. Spears, I. Donnelly, L. Jolly et al., “Bronchodilatory eﬀect
of the PPAR-gamma agonist rosiglitazone in smokers with
asthma,” Clinical Pharmacology and Therapeutics, vol. 86, no.
1, pp. 49–53, 2009.
[53] S. Ueki, T. Adachi, J. Bourdeaux et al., “Expression of
PPARgamma in eosinophils and its functional role in survival
and chemotaxis,” Immunology Letters, vol. 86, no. 2, pp. 183–
189, 2003.
[54] H. Hirasawa, T. Chiba, S. Ueki et al., “The synthetic
PPARgamma agonist troglitazone inhibits eotaxin-enhanced
eosinophil adhesion to ICAM-1-coated plates,” International
archives of allergy and immunology, vol. 146, supplement 1, pp.
11–15, 2008.
[55] P. R. Hanlon, L. G. Ganem, Y. C. Cho, M. Yamamoto, and
C. R. Jefcoate, “AhR- and ERK-dependent pathways function
synergisticallytomediate2,3,7,8-tetrachlorodibenzo-p-dioxin
suppression of peroxisome proliferator-activated receptor-
gamma1 expression and subsequent adipocyte diﬀerentia-
tion,”ToxicologyandAppliedPharmacology,vol.189,no.1,pp.
11–27, 2003.
[ 5 6 ]Y .C .C h o ,W .Z h e n g ,M .Y a m a m o t o ,X .L i u ,P .R .H a n l o n ,
and C. R. Jefcoate, “Diﬀerentiation of pluripotent C3H10T1/2
cells rapidly elevates CYP1B1 through a novel process that
overcomes a loss of Ah receptor,” Archives of Biochemistry and
Biophysics, vol. 439, no. 2, pp. 139–153, 2005.
[57] M. Tauchi, A. Hida, T. Negishi et al., “Constitutive expression
of aryl hydrocarbon receptor in keratinocytes causes inﬂam-
matory skin lesions,” Molecular and Cellular Biology, vol. 25,
no. 21, pp. 9360–9368, 2005.
[58] R. S. Marcus, M. P. Holsapple, and N. E. Kaminski, “Lipo-
polysaccharide activation of murine splenocytes and splenic
B cells increased the expression of aryl hydrocarbon receptor
and aryl hydrocarbon receptor nuclear translocator,” Journal
of Pharmacology and Experimental Therapeutics, vol. 287, pp.
1113–1118, 1998.
[59] H. Takenaka, K. Zhang, D. Diaz-Sanchez, A. Tsien, and A.
Saxon, “Enhanced human IgE production results from expo-
sure to the aromatic hydrocarbons from diesel exhaust: direct
eﬀects on B-cell IgE production,” Journal of Allergy and
Clinical Immunology, vol. 95, no. 1, pp. 103–115, 1995.
[60] E. Bettelli, T. Korn, M. Oukka, and V. K. Kuchroo, “Induction
and eﬀe c t o rf u n c t i o n so fT ( H ) 1 7c e l l s , ”Nature, vol. 453, no.
7198, pp. 1051–1057, 2008.
[61] F. J. Quintana, A. S. Basso, A. H. Iglesias et al., “Control of
T(reg)andT(H)17celldiﬀerentiationbythearylhydrocarbon
receptor,” Nature, vol. 453, no. 7191, pp. 65–71, 2008.
[62] L. A. Tesmer, S. K. Lundy, S. Sarkar, and D. A. Fox, “Th17 cells
in human disease,” Immunological Reviews, vol. 223, no. 1, pp.
87–113, 2008.
[63] S. L. Gaﬀen, “An overview of IL-17 function and signaling,”
Cytokine, vol. 43, no. 3, pp. 402–407, 2008.
[64] K. Oboki, T. Ohno, H. Saito, and S. Nakae, “Th17 and allergy,”
Allergology International, vol. 57, no. 2, pp. 121–134, 2008.
[65] J .F .Alc orn,C.R.C r o w e,andJ .K.K olls,“TH17c ellsinasthma
andCOPD,”Annual Review of Physiology,vol.72,pp.495–516,
2009.
[66] S. Schnyder-Candrian, D. Togbe, I. Couillin et al., “Interleu-
kin-17 is a negative regulator of established allergic asthma,”
Journal of Experimental Medicine, vol. 203, no. 12, pp. 2715–
2725, 2006.8 Journal of Allergy
[67] O. Prause, S. Bozinovski, G. P. Anderson, and A. Lind´ en,
“Increased matrix metalloproteinase-9 concentration and
activity after stimulation with interleukin-17 in mouse air-
ways,” Thorax, vol. 59, no. 4, pp. 313–317, 2004.
[68] J.M.Ramirez,N.C.Brembilla,O.Sorgetal.,“Activationofthe
arylhydrocarbonreceptorrevealsdistinctrequirementsforIL-
22 and IL-17 production by human T helper cells,” European
Journal of Immunology, vol. 40, no. 9, pp. 2450–2459, 2010.